Indication: For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer
Pharmacology: Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose.
Mechanism Of Action: The mechanism by which Dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that Dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.
Absorption: IV administration results in complete bioavailability.
Interactions:
DrugBank: Interactions for Dexrazoxane
Interactions for Dexrazoxane:
ZINECARD does not influence the pharmacokinetics of doxorubicin.
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried
out with dexrazoxane in animals. Dexrazoxane was not mutagenic in the Ames test but was found to be clastogenic to
human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test).
The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have
not been adequately studied. Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg
weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13
weeks in dogs (approximately equal to the human dose on a mg/m 2 basis).
Chemical IUPAC Name: 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
